| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e3c90dc835ada77be791af3763ebbca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
| filingDate |
2017-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fee683a4b6a04bad06b95cd9c82cdad3 |
| publicationDate |
2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018039221-A1 |
| titleOfInvention |
Live attenuated recombinant hmpv with mutations in pdz motifs of m2-2 protein, vaccine containing and use thereof |
| abstract |
The present application generally relates to the development of live attenuated Pneumoviridae strains suitable for use as a vaccine. Particularly, human metapneumovirus (hMPV) ΔM2-2 strains (rhMPV-E30M31 and rhMPV-E40L42D44) containing point mutations in a PDZ motif of M2-2, which results in a strain that is both attenuated and immunogenic and, notably, maintains the function of F and G proteins. These live attenuated hMPV strains should be suitable for use in a vaccine capable of providing protection against respiratory infection elicited by hMPV. Additionally, human respiratory syncytial virus (hRSV) strains containing point mutations in a PDZ motif of M2-2 should also be suitable for use as a vaccine capable of providing protection against respiratory infection elicited by hRSV. These Pneumoviridae strains should be useful in vaccines for use in humans and animals, e.g., companion animals and livestock, in treating or providing immunoprotection against respiratory infections. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109402065-A |
| priorityDate |
2016-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |